Clinical Trials Browser

Recruiting × Breast Neoplasms × Combined Modality Therapy × Clear all

NCT05228951 2022-09-13

Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC

Phase 2 Recruiting

Breast Neoplasms